Extended-release granisetron polymer formulation

{
  "id": "MLC-T-ONC-013492",
  "term": "Extended-release granisetron polymer formulation",
  "field": "Oncology and biomedicine",
  "definition": "An extended-release (ER), polymer-based injectable formulation containing the indazole derivative granisetron, a selective serotonin (5-hydroxytryptamine; 5-HT) receptor type 3 (5-HT3) antagonist, with anti-emetic activity. Upon subcutaneous administration, granisetron is released from the polymer in a sustained manner, which is based upon the controlled hydrolysis of the polymers, and selectively binds to and inhibits the activity of the 5-HT3 receptors located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone (CTZ) of the area postrema. By preventing stimulation of 5-HT3 receptors, granisetron is able to suppress chemotherapy-induced nausea and vomiting (CINV). Compared to the injection of granisetron alone, injection of the polymer-based formulation allows for therapeutic levels of granisetron over an extended period of time.",
  "synonyms": [
    "ER granisetron injectable formulation",
    "granisetron extended-release injection",
    "granisetron extended-release polymer-based injectable formulation"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/extended-release-granisetron-polymer-formulation/"
}